JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution

Editas Medicine Inc. EDIT announced last week a strategic realignment to focus on in vivo gene editing.

The shift is designed to optimize costs, extend its cash runway into the second quarter of 2027, and accelerate its progress toward achieving human proof of concept within two years.

Also Read: Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

JPMorgan spoke with Editas management. The analyst said that, overall, they were surprised by the timing of the restructuring. While there are personnel and legal considerations, the pivot would be better received if delivered in a single step, the analyst wrote.

JPMorgan highlighted the strategic move to prioritize in vivo programs, but noted that clarity is needed on the next steps and the timeline for initial human proof-of-concept results.

Until more visibility is gained, investors may remain cautious, keeping Editas Medicine shares trading within a limited range compared to peers in the coverage.

The analyst saw significant value embedded in its technical expertise and IP estate. However, the next major inflection point in the stock is still a way away, and investors will want to see the first clinical proof of concept before returning to the story.

As such, Editas Medicine shares will underperform relative to other names in JPMorgan’s coverage universe for now. The analyst downgraded the rating to Underweight from Neutral.

The recent strategic updates, including workforce cuts and management/board departures, may raise concerns about Editas Medicine’s shift toward in vivo development. JP Morgan added that these changes could suggest further adjustments to its development strategy in the future.

EDIT Price Action: Editas Medicine stock is up 2.36% at $1.52 at publication Tuesday.

Read Next:

• What’s Going On With Illumina Stock On Monday?

Photo: Gorodenkoff/Shutterstock.com